Size Matters: Novartis Says Vaccines are for Big Manufacturers, Marketers
This article was originally published in RPM Report
Executive Summary
The vaccine business is made-to-order for Big Pharma. That's how Novartis is portraying the business to the financial community-a good growing environment if you can afford to reach scale. One of Novartis' partners in development, the Austrian firm Intercell, has also become a hot performer based on its strong piipeline of projects. Maybe there is room for both large and small.
You may also be interested in...
Novartis Bets Big on Meningitis:Wall Street Awaits Blockbuster Vaccine Franchise
Two years after shaking up the vaccine field with its big entry-acquisition of Chiron, Novartis AG has identified a make-or-break pair of projects in the meningitis area. The meningitis vaccines will determine whether the Novartis bet on vaccines will turn into a smart long-term diversification or a low-return move into an unfamiliar and unfriendly segment of health care.
Novartis Bets Big on Meningitis:Wall Street Awaits Blockbuster Vaccine Franchise
Two years after shaking up the vaccine field with its big entry-acquisition of Chiron, Novartis AG has identified a make-or-break pair of projects in the meningitis area. The meningitis vaccines will determine whether the Novartis bet on vaccines will turn into a smart long-term diversification or a low-return move into an unfamiliar and unfriendly segment of health care.
Novartis/Chiron: Validating the Value of Vaccine R&D
Nothing solidifies the emergence of a hot investment sector like a big investment of cash, and Novartis AG provided that with its two-stage $5.7 billion close out of the remaining shares of Chiron Corp. that it did not already own (W#200510159). Novartis bought $300 million worth of Chiron's stock in December 2005 and then closed out the deal with $5.4 billion in April 2006.